ES2130118T3 - Peptidos ciclicos con actividad antiagregante. - Google Patents

Peptidos ciclicos con actividad antiagregante.

Info

Publication number
ES2130118T3
ES2130118T3 ES90311537T ES90311537T ES2130118T3 ES 2130118 T3 ES2130118 T3 ES 2130118T3 ES 90311537 T ES90311537 T ES 90311537T ES 90311537 T ES90311537 T ES 90311537T ES 2130118 T3 ES2130118 T3 ES 2130118T3
Authority
ES
Spain
Prior art keywords
arg
alk
min min
phe
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90311537T
Other languages
English (en)
Inventor
Fadia El-Fehail Ali
James Martin Samanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2130118T3 publication Critical patent/ES2130118T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPONENTES QUE TIENEN LA FORMULA: EN LA QUE: A'' ES MEXISTENTE, A SUB SN, G SUB LN, A SUB LA O A SUB BN; A ES INEXISTENTE, O UN DENTRE A SUB RG, HA SUB RG, (M SUB E2)A SUB RG, (E SUB T2)A SUB RG, A SUB BU, A SUB LA, G SUB LY, H SUB IS, L SUB YS, O UN (ALFA)-R'' SUSTITUTO DERIVATIVO DE AQUIL, D SUB TC, T SUB PR O P SUB RO; B ES UN D-O-L AMINO-ACIDO ELEGIDO ENTRE A SUB RG, HA SUB RG, (M SUB EZ) A SUB RG, (E SUB T2)A SUB RG, L SUB YS O UN (ALFA)-R'' SUSTITUTO DERIVATIVO DE AQUIL; Q ES INEXISTENTE A UN D O L AMINO-ACIDO ELEGIDO ENTRE T SUB YR, (A SUB LK) T SUB YR, P SUB HE, (4''W)P SUB HE, HP SUB HE, P SUB HG, P SUB RO, T SUB RP, H SUB IS, S SUB ER, (A SUB LK)S SUB ER, T SUB HR, (A SUB LK)T SUB HR, (A SUB LK)C SUB YS, (A SUB LK)P SUB NE, A SUB LA, V SUB AL, N SUB VA, M SUB ET, L SUB EU, L SUB LE, N SUB LE O N SUB AL, O UN (ALFA)-R'' SUSTITUTIVO DERIVATIVO DE AQUIL. M ES G SUB LY O D O L G SUB LU, P SUB HE, P SUB RO, L SUB YS, S SUB ER O, SIEMPRE QUE N SEA 1, B-G SUB LY -G SUB LU -Q; W ES ALOGENO O A SUB LK; R'' ES A SUB LK O P SUB H CH SUB 2;
ES90311537T 1989-10-23 1990-10-22 Peptidos ciclicos con actividad antiagregante. Expired - Lifetime ES2130118T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42590689A 1989-10-23 1989-10-23

Publications (1)

Publication Number Publication Date
ES2130118T3 true ES2130118T3 (es) 1999-07-01

Family

ID=23688530

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90311537T Expired - Lifetime ES2130118T3 (es) 1989-10-23 1990-10-22 Peptidos ciclicos con actividad antiagregante.

Country Status (13)

Country Link
EP (1) EP0425212B1 (es)
JP (1) JP2922281B2 (es)
KR (1) KR910007964A (es)
AT (1) ATE178613T1 (es)
AU (1) AU6470590A (es)
CA (1) CA2027936C (es)
CZ (1) CZ397991A3 (es)
DE (1) DE69033038T2 (es)
ES (1) ES2130118T3 (es)
IE (1) IE903775A1 (es)
NZ (1) NZ235767A (es)
PT (1) PT95661B (es)
ZA (1) ZA908426B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795867A (en) * 1989-06-16 1998-08-18 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5686568A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregration inhibitors
NZ235564A (en) * 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
US5360811A (en) * 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5721210A (en) * 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
EP0555328A1 (en) * 1990-11-02 1993-08-18 Genentech, Inc. Platelet aggregation inhibitors
ES2141102T3 (es) * 1991-02-08 2000-03-16 Diatide Inc Polipeptidos marcados con tecnecio-99m para la generacion de imagenes.
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US5830856A (en) * 1991-02-08 1998-11-03 Diatide, Inc. Radiolabeled compounds for thrombus imaging
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US6107459A (en) * 1991-02-08 2000-08-22 Diatide, Inc. Technetium-99m labeled peptides for diagnostic imaging
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
IL103252A (en) 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
US5565449A (en) * 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5338725A (en) * 1992-06-30 1994-08-16 The Research Foundation Of The State University Of New York Anti-aggregatory agents for platelets
CA2101599A1 (en) * 1992-08-31 1994-03-01 Wilhelm Bannwarth Tri- and tetracyclic compounds
DK0665853T3 (da) * 1992-10-02 2002-11-04 Diatide Inc Multimere polyvalente antitrombotiske midler
AU5594294A (en) * 1992-11-18 1994-06-08 Du Pont Merck Pharmaceutical Company, The Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein iib/iiia
EP0691986B1 (en) * 1993-03-29 1998-12-02 The Du Pont Merck Pharmaceutical Company NOVEL PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PLATELET CLYCOPROTEIN IIb/IIIa INHIBITORS
CA2159070A1 (en) * 1993-03-29 1994-10-13 William Frank Degrado Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE69431052T2 (de) * 1993-04-08 2003-03-13 Diatide, Inc. Radiomarkierte verbindungen zur thrombus-bilderzeugung
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6635738B2 (en) 1996-03-04 2003-10-21 The Trustees Of Columbia University In The City Of New York Compounds which prevent neuronal cell death and uses thereof
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6685914B1 (en) 1999-09-13 2004-02-03 Bristol-Myers Squibb Pharma Company Macrocyclic chelants for metallopharmaceuticals
AU2001236065A1 (en) * 2000-03-03 2001-09-12 Nobutaka Fujii Antiviral compounds
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
EP2845601B1 (en) * 2010-11-01 2018-04-25 Industry-Academic Cooperation Foundation, Yonsei University Composition for use for dissolving thrombi
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
CN105152989B (zh) * 2015-09-16 2017-05-10 复旦大学 一种(1r,2r)‑1‑取代苯基‑2‑氨基‑1,3‑丙二醇的制备方法
CN107540728A (zh) * 2017-07-07 2018-01-05 安徽工程大学 环（Phe‑Pro‑lle‑Phe‑Pro‑Pro‑Leu‑Val）肽的制备方法
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN112125953B (zh) * 2020-07-23 2022-09-16 昆明医科大学第一附属医院 一种抗血小板聚集的多肽
CN113429457B (zh) * 2021-06-16 2022-07-26 昆明医科大学第一附属医院 一种抗血小板聚集的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US890432A (en) 1907-08-02 1908-06-09 John Roy Masson Wet process of recovering antimony in a pure state from ores, concentrates, tailings, and slimes containing it.
SU822551A1 (ru) 1979-08-30 1986-07-30 Всесоюзный кардиологический научный центр АМН СССР Стабилизированна стрептокиназа,обладающа тромболитической активностью
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
GR78180B (es) 1982-04-15 1984-09-26 Genentech Inc
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
IT1189379B (it) 1982-10-08 1988-02-04 Serono Ist Farm Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
GB8334498D0 (en) 1983-12-24 1984-02-01 Beecham Group Plc Compounds
ZW14486A1 (en) 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4683291A (en) 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
US4687758A (en) 1985-11-19 1987-08-18 Smithkline Beckman Corporation Des-proline-N-methylarginine vasopressins
PT84587B (pt) 1986-04-02 1989-11-30 Beecham Group Plc Processo para preparacao de uma enzima fibrinolitica
EP0275748B1 (fr) * 1986-12-15 1992-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
EP0297882B1 (en) 1987-07-01 1993-08-25 Beecham Group Plc Hybrid plasminogen activators
AU639409B2 (en) * 1987-12-10 1993-07-29 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
EP0410541A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0410540A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
IT1238987B (it) * 1990-01-31 1993-09-17 Vouk Macchine Tessili Spa Macchina pettinatrice e rispettivi gruppi pettinatori semplificati
WO1991015224A1 (en) * 1990-03-30 1991-10-17 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
EP0425212B1 (en) 1999-04-07
CZ397991A3 (en) 1993-06-16
PT95661A (pt) 1991-09-13
NZ235767A (en) 1992-08-26
ZA908426B (en) 1991-07-31
CA2027936A1 (en) 1991-04-24
DE69033038D1 (de) 1999-05-12
EP0425212A3 (en) 1991-09-18
JPH03161498A (ja) 1991-07-11
ATE178613T1 (de) 1999-04-15
DE69033038T2 (de) 1999-11-11
KR910007964A (ko) 1991-05-30
PT95661B (pt) 1998-03-31
CA2027936C (en) 2001-07-24
JP2922281B2 (ja) 1999-07-19
EP0425212A2 (en) 1991-05-02
IE903775A1 (en) 1991-04-24
AU6470590A (en) 1991-04-26

Similar Documents

Publication Publication Date Title
ES2130118T3 (es) Peptidos ciclicos con actividad antiagregante.
HUT49891A (en) Process for production of peptides with antiaggregation effect and medical compositions containing them
Ljungqvist et al. Antide and related antagonists of luteinizing hormone release with long action and oral activity.
AU589674B2 (en) GRF analogs
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
EP0333356A3 (en) Hirudin peptides
CA2050300A1 (en) Tnf-inhibiting proteins and the preparation thereof
KR0173976B1 (ko) 브라디키닌에 대하여 길항작용을 하는 펩타이드
Klein et al. Pressor and cardioaccelerator effects of gamma MSH and related peptides
ES2054365T3 (es) Inhibicion de la via de la regla del n final en celulas vivas.
KR910002900A (ko) 합성 펩티드 및 이를 함유하는 제약학적 조성물
KR880013977A (ko) 항응고제인 사이클릭 펩타이드
KR880013976A (ko) 항응고제인 사이클릭 펩타이드
EP0796867A4 (en) PEPTIDE, BRONCHODILATOR AND AGENT FOR FACILITATING BLOOD FLOW
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
KR920018074A (ko) 사이클릭 항-응집성 펩티드
SI9300595B (sl) Peptidi z organo-protektivno aktivnostjo, postopki za njihovo pripravo in njihova uporaba v terapiji
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 425212

Country of ref document: ES